Pancreatic cancer is one of the deadliest diseases. Nearly 80% of patients die one year after diagnosis. Studies have shown a link between the formation of blood clots and pancreatic cancer. Blood clots are formed mainly by platelets; tiny cells that clump together when activated.

Our study has found that a commonly used blood thinner may help pancreatic cancer patients.

Pancreatic cancer cells activate platelets, leading to blood clot formation. In return, platelets secrete growth factors to fuel pancreatic cancer and boost chemotherapy resistance. We found that a commonly used blood thinner blocked cancer-platelet crosstalk, reduced the growth of pancreatic cancer cells in “test-tubes” and promoted the effectiveness of chemotherapy in mice with pancreatic cancer.

While more experimental data is required before we can move forward to human therapy, this study provides promising laboratory-based evidence.

PBI scientists are active in delivering research papers and oral presentations to the scientific and medical community